Is Harvard Bioscience Stock a Good Investment?
Harvard Bioscience Investment Advice | HBIO |
- Examine Harvard Bioscience's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Harvard Bioscience's leadership team and their track record. Good management can help Harvard Bioscience navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Life Sciences Tools & Services space and any emerging trends that could impact Harvard Bioscience's business and its evolving consumer preferences.
- Compare Harvard Bioscience's performance and market position to its competitors. Analyze how Harvard Bioscience is positioned in terms of product offerings, innovation, and market share.
- Check if Harvard Bioscience pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Harvard Bioscience's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Harvard Bioscience stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Harvard Bioscience is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Abnormally volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Harvard Bioscience Stock
Researching Harvard Bioscience's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 82.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.44. Some equities with similar Price to Book (P/B) outperform the market in the long run. Harvard Bioscience has Price/Earnings To Growth (PEG) ratio of 2.89. The entity recorded a loss per share of 0.28. The firm had not issued any dividends in recent years. Harvard Bioscience had 1319:1000 split on the 4th of November 2013.
To determine if Harvard Bioscience is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Harvard Bioscience's research are outlined below:
| Harvard Bioscience generated a negative expected return over the last 90 days | |
| Harvard Bioscience has some characteristics of a very speculative penny stock | |
| Harvard Bioscience has high historical volatility and very poor performance | |
| Harvard Bioscience has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 94.14 M. Net Loss for the year was (12.4 M) with profit before overhead, payroll, taxes, and interest of 54.81 M. | |
| Over 82.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 38413 shares by James Green of Harvard Bioscience at 0.6886 subject to Rule 16b-3 |
Harvard Bioscience Quarterly Long Term Debt |
|
Harvard Bioscience uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Harvard Bioscience. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Harvard Bioscience's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 23rd of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Harvard Bioscience's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Harvard Bioscience's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-03-05 | 2024-12-31 | 0.05 | 0.06 | 0.01 | 20 | ||
2024-03-07 | 2023-12-31 | 0.05 | 0.04 | -0.01 | 20 | ||
2023-04-25 | 2023-03-31 | 0.05 | 0.06 | 0.01 | 20 | ||
2023-03-09 | 2022-12-31 | 0.03 | 0.04 | 0.01 | 33 | ||
2022-08-03 | 2022-06-30 | 0.06 | 0.05 | -0.01 | 16 | ||
2022-05-04 | 2022-03-31 | 0.05 | 0.04 | -0.01 | 20 | ||
2021-03-10 | 2020-12-31 | 0.07 | 0.08 | 0.01 | 14 | ||
2020-02-26 | 2019-12-31 | 0.09 | 0.08 | -0.01 | 11 |
Know Harvard Bioscience's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Harvard Bioscience is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Harvard Bioscience backward and forwards among themselves. Harvard Bioscience's institutional investor refers to the entity that pools money to purchase Harvard Bioscience's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 919.1 K | Meros Investment Management, Lp | 2024-12-31 | 813.7 K | State Street Corp | 2024-12-31 | 742.6 K | Renaissance Technologies Corp | 2024-12-31 | 709.8 K | Acuitas Investments, Llc | 2024-12-31 | 491.1 K | Northern Trust Corp | 2024-12-31 | 449 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 278.2 K | Bard Associates Inc | 2024-12-31 | 267.7 K | Charles Schwab Investment Management Inc | 2024-12-31 | 239.7 K | Blackrock Inc | 2024-12-31 | 3 M | Punch & Associates Inv Mgmt Inc | 2024-12-31 | 2.8 M |
Harvard Bioscience's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 28.04 M.Market Cap |
|
Harvard Bioscience's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.21) | (0.22) | |
| Return On Capital Employed | (0.09) | (0.08) | |
| Return On Assets | (0.10) | (0.10) | |
| Return On Equity | (0.20) | (0.21) |
Determining Harvard Bioscience's profitability involves analyzing its financial statements and using various financial metrics to determine if Harvard Bioscience is a good buy. For example, gross profit margin measures Harvard Bioscience's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Harvard Bioscience's profitability and make more informed investment decisions.
Evaluate Harvard Bioscience's management efficiency
Harvard Bioscience has return on total asset (ROA) of (0.0223) % which means that it has lost $0.0223 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1819) %, meaning that it created substantial loss on money invested by shareholders. Harvard Bioscience's management efficiency ratios could be used to measure how well Harvard Bioscience manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of March 2025, Return On Tangible Assets is likely to drop to -0.22. In addition to that, Return On Capital Employed is likely to grow to -0.08. At this time, Harvard Bioscience's Total Current Assets are very stable compared to the past year. As of the 24th of March 2025, Non Currrent Assets Other is likely to grow to about 4.1 M, while Total Assets are likely to drop about 125.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.45 | 2.81 | |
| Tangible Book Value Per Share | (0.09) | (0.09) | |
| Enterprise Value Over EBITDA | (101.81) | (96.72) | |
| Price Book Value Ratio | 1.45 | 1.38 | |
| Enterprise Value Multiple | (101.81) | (96.72) | |
| Price Fair Value | 1.45 | 1.38 | |
| Enterprise Value | 238.9 M | 250.8 M |
The operational strategies employed by Harvard Bioscience management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Beta 1.468 |
Basic technical analysis of Harvard Stock
As of the 24th of March, Harvard Bioscience retains the Market Risk Adjusted Performance of (0.81), risk adjusted performance of (0.35), and Standard Deviation of 4.31. Harvard Bioscience technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Harvard Bioscience's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Harvard Bioscience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Harvard Bioscience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Harvard Bioscience insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Harvard Bioscience's Outstanding Corporate Bonds
Harvard Bioscience issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Harvard Bioscience uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Harvard bonds can be classified according to their maturity, which is the date when Harvard Bioscience has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Harvard Bioscience's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Harvard Bioscience's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.35) | |||
| Market Risk Adjusted Performance | (0.81) | |||
| Mean Deviation | 3.41 | |||
| Coefficient Of Variation | (248.68) | |||
| Standard Deviation | 4.31 | |||
| Variance | 18.54 | |||
| Information Ratio | (0.39) | |||
| Jensen Alpha | (1.60) | |||
| Total Risk Alpha | (1.41) | |||
| Treynor Ratio | (0.82) | |||
| Maximum Drawdown | 21.52 | |||
| Value At Risk | (9.21) | |||
| Potential Upside | 4.21 | |||
| Skewness | (0.64) | |||
| Kurtosis | 1.02 |
| Risk Adjusted Performance | (0.35) | |||
| Market Risk Adjusted Performance | (0.81) | |||
| Mean Deviation | 3.41 | |||
| Coefficient Of Variation | (248.68) | |||
| Standard Deviation | 4.31 | |||
| Variance | 18.54 | |||
| Information Ratio | (0.39) | |||
| Jensen Alpha | (1.60) | |||
| Total Risk Alpha | (1.41) | |||
| Treynor Ratio | (0.82) | |||
| Maximum Drawdown | 21.52 | |||
| Value At Risk | (9.21) | |||
| Potential Upside | 4.21 | |||
| Skewness | (0.64) | |||
| Kurtosis | 1.02 |
Consider Harvard Bioscience's intraday indicators
Harvard Bioscience intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Harvard Bioscience stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 0.0615 | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 0.63 | |||
| Day Typical Price | 0.63 | |||
| Market Facilitation Index | 0.04 | |||
| Price Action Indicator | 0.01 | |||
| Relative Strength Index | 9.94 |
Harvard Stock media impact
Far too much social signal, news, headlines, and media speculation about Harvard Bioscience that are available to investors today. That information is available publicly through Harvard media outlets and privately through word of mouth or via Harvard internal channels. However, regardless of the origin, that massive amount of Harvard data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Harvard Bioscience news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Harvard Bioscience relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Harvard Bioscience's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Harvard Bioscience alpha.
Harvard Bioscience Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Harvard Bioscience can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Harvard Bioscience Corporate Management
| Ryan Wallace | Senior Sales | Profile | |
| Michael Rossi | Chief Officer | Profile | |
| Kara Weiner | VP Management | Profile | |
| David Sirois | Director Reporting | Profile | |
| Kenneth Olson | Ex Officer | Profile | |
| Kathryn Flynn | Corporate Controller | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harvard Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harvard Bioscience. If investors know Harvard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harvard Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.80) | Earnings Share (0.28) | Revenue Per Share | Quarterly Revenue Growth (0.13) | Return On Assets |
The market value of Harvard Bioscience is measured differently than its book value, which is the value of Harvard that is recorded on the company's balance sheet. Investors also form their own opinion of Harvard Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Harvard Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harvard Bioscience's market value can be influenced by many factors that don't directly affect Harvard Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Harvard Bioscience's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Harvard Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harvard Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.